Pular para o conteúdo
Merck
  • Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

The Journal of pharmacology and experimental therapeutics (2016-12-15)
J Di Salvo, H Nagabukuro, L A Wickham, C Abbadie, J A DeMartino, A Fitzmaurice, L Gichuru, A Kulick, M J Donnelly, N Jochnowitz, A L Hurley, A Pereira, A Sanfiz, G Veronin, K Villa, J Woods, B Zamlynny, E Zycband, G M Salituro, T Frenkl, A E Weber, S D Edmondson, M Struthers
RESUMO

Although the physiologic role of muscarinic receptors in bladder function and the therapeutic efficacy of muscarinic antagonists for the treatment of overactive bladder are well established, the role of β

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
CL 316,243 hydrate, ≥98% (HPLC), powder
Sigma-Aldrich
Kits e reagentes de triglicerídeos e glicerol livre, 1 kit sufficient for 1000 reactions
Sigma-Aldrich
Methoctramine hydrate, ≥97% (NMR), solid
Sigma-Aldrich
Darifenacin hydrobromide, ≥98% (HPLC)